- 1 Comorbidities associated with chronic kidney disease among young people living with HIV in
- 2 Uganda. A nested case control study
- 3 Esther M Nasuuna ^{1,2,3}, Laurie A Tomlinson⁴, Robert Kalyesubula^{1,5}, Barbara Castelnuovo², Nicholus
- 4 Nanyeenya⁶, Chido Dziva Chikwari ^{7,8}, Helen A Weiss⁸
- 5 1 Non-communicable Diseases Program, Medical Research Council/Uganda Virus Research Institute
- 6 and London School of Hygiene and Tropical Medicine Uganda Research Unit, Plot 51-59 Nakiwogo
- 7 Road, Entebbe Uganda
- 8 2 Infectious Diseases Institute, Makerere University, College of Health Sciences, P.O.Box 22418
- 9 Kampala, Uganda
- 10 3 Department of Infectious Disease Epidemiology and International Health, London School of
- 11 Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, United Kingdom.
- 12 4 Department of non-Communicable Disease Epidemiology, London School of Hygiene and Tropical
- 13 Medicine, Keppel St, London WC1E 7HT, United Kingdom
- 14 5 Department of Physiology and Department of Medicine, Makerere University College of Health
- 15 Sciences, P.O. Box 7072, Kampala, Uganda
- 16 6 School of Public Health, Makerere University College of Health Sciences, P.O. Box 7072, Kampala,
- 17 Uganda

25

32 33

- 18 7 Biomedical Research and Training Institute, 10 Seagrave Avondale, Harare, Zimbabwe
- 19 8 MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical
- 20 Medicine, Keppel St, London WC1E 7HT, United Kingdom
- 22 Corresponding author
- 23 Esther M Nasuuna
- 24 Esther.nasuuna@lshtm.ac.uk
- 26 Laurie A Tomlinson: laurie.tomlinson@lshtm.ac.uk
- 27 Robert Kalyesubula: rkalyesubula@gmail.com
- 28 Barbara Castelnuovo:bcastelnuovo@gmail.com
- 29 Nicholus Nanyeenya: nanyeenya@gmail.com
- 30 Chido Dziva Chikwari: chidodziva.chikwari@lshtm.ac.uk
- 31 Helen A Weiss: helen.weiss@lshtm.ac.uk

36

37

38

39

41

44

46

47

51

53

54

55

56

57

58

Abstract 35 Introduction Chronic kidney disease (CKD) is often complicated by disorders in multiple body systems, associated with higher mortality and morbidity. Young people living with HIV (YPLHIV) have an increased risk of multisystem chronic comorbidities. However, there are few data describing comorbidities associated with CKD among YPLHIV. 40 Methods We conducted a case-control study in seven ART clinics in Kampala, Uganda. Cases were YPLHIV 42 (aged 10-24 years) diagnosed with CKD and controls were those without CKD. We collected data on 43 demographic and clinical factors: blood pressure, fasting glucose levels, anaemia, electrolytes, parathyroid hormone, and cognitive impairment. We summarized the demographic and clinical factors 45 and used logistic regression to estimate odds ratios (OR) and 95% confidence intervals for associations between CKD comorbidities, adjusted for age, sex and viral suppression. **Results** 48 A total of 292 participants (96 cases and 196 controls) were recruited. Cases were mostly male (59.4% 49 vs 36.5%), and younger (88.5% vs 46.4% aged <17 years) compared to controls. CKD was associated 50 with having a detectable HIV viral load (OR=3.73; 95% CI 1.53-9.12) and proteinuria (aOR=4.19; 95% CI 2.28-7.72). CKD was also associated with low haematocrit, hypochloraemia, 52 hyperphosphatemia, and high mean corpuscular volume. There was no evidence of an association of CKD with hypertension, anaemia, or stunting. Conclusion The pattern of comorbidities among YPLHIV with CKD is uncertain and difficulties may relate to difficulty determining true kidney function and normal ranges in this population. Further studies are needed to discern the pattern of CKD complications to improve management efforts and clinical outcomes.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

Key words. Chronic kidney disease, complications, young people living with HIV, Sub Saharan Africa Introduction Chronic kidney disease (CKD) is often complicated by disorders in multiple body systems as the kidneys play a pivotal role in homeostasis maintenance in the body [1]. With extensive damage and progressive decline in function, the kidney is unable to perform its many functions and other body systems are affected [2]. The most commonly affected systems are the haematological, cardiovascular, endocrine, and musculoskeletal [3, 4]. CKD comorbidities and complications increase with reducing kidney function and are associated with higher mortality, morbidity, and reduced quality of life [5]. In people with CKD, cardiovascular complications such as congestive cardiac failure, arrhythmias, and coronary artery disease are common, and are leading cause of mortality [6, 7]. Hypertension also commonly complicates CKD and leads to faster deterioration in glomerular filtration rate [8]. Anaemia is the commonest haematological complication of CKD resulting partially from the reduced production of erythropoietin in the damaged kidneys [4]. In the musculoskeletal system, disordered bone mineral metabolism of calcium, phosphorus and parathyroid hormone leads to osteodystrophy and osteoporosis that predispose to fractures and stunting in children [9-11]. The most common neurological complications are cognitive impairment, stroke, encephalopathy, autonomic and peripheral neuropathies [3, 12]. If these complications are undiagnosed and untreated, they will eventually lead to death [2]. Young people living with HIV (YPLHIV) have an increased risk of multisystem chronic comorbidities as a result of the HIV infection itself [13]. When YPLHIV develop CKD, the risk of comorbidities is increased due to the additional burden of gradual deterioration in kidney function [5, 14]. There is a poorly understood complex interplay between HIV and CKD that makes it difficult to determine if HIV or CKD or their combination is driving the development of the complications [15]. Current literature that is derived mostly from high income countries, describes the presentation and

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

comorbidities of CKD in adults that are mostly caused by living with hypertension and diabetes, or in children with mostly congenital causes [16]. These comorbidities may differ from those in young adults living with HIV and CKD in LMICs, and we need to understand such differences, especially if they have clinical implications. Kidney disease improving global outcomes (KDIGO) recommends the consistent documentation of all laboratory abnormalities in different populations with CKD to inform management practices and improve associated quality of life, morbidity and mortality [5]. Therefore, we sought to describe the comorbidities and complications and associations with kidney function in YPLHIV in Uganda. **Materials and Methods** Study design, setting and population. This case-control study with 96 cases and 196 controls was conducted in seven urban ART clinics in Kampala, Uganda between November 2023 and January 2024. Sampling: The cases were the YPLHIV (aged 10 to 24 years) diagnosed with CKD. This was defined as an eGFR below 90ml/min/1.73m² on two separate occasions three or more months apart using cystatin C based Schwartz equation [17] without restriction for age. We elected to use this approach as sudden switch to adult formulae at age 18 have been shown to overestimate GFR and it has been recommended to use paediatric formulae for adolescents and young adults up to age 30 when concurrence between eGFR from adult and paediatric formulae happens [18, 19]. We used a cut off of 90ml/min/1.73m² and not the standard <60ml/min/1.73m² as we were studying a young population where GFR well above 60ml/min/1.73m² would have been anticipated in health, and stage 2 CKD is diagnosed between 89 and 60ml/min/1.73m² if there is evidence of persisting kidney damage [20-22]. Separately, we also described parameters among individuals with eGFR<60ml/min/1.73m². Serum cystatin C was measured in a batch by particle-enhanced immunoturbidimetric assay on Roche Cobas C311 platform with Tina-quant Cystatin C Gen.2 [23].

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

The controls were the YPLHIV attending the same clinics with an eGFR equal to or above 90ml/min/1.73m² determined with the same methods as the cases. We recruited two controls for each case. Study procedures: Participants were invited to the facility where they were interviewed about current medication and hospitalisation. Data were collected on the demographic variables (age, sex, religion, school status, tribe, address). School status was either in school or out if school, address was collected as either living in Kampala or out of Kampala. Clinical variables collected were: stunting according to the WHO reference standard, body mass index calculated as weight over height squared, mid upper arm circumference (MUAC) was measured using the UNICEF tapes according to the age of the participant, HIV viral suppression was defined as an HIV viral load below 1000 cells/ml, proteinuria was defined as either trace of 1+ and above on dipstick, albumin creatinine ratio (ACR) was measured in the laboratory and whether or not the participant was on a tenofovir disoproxil fumarate (TDF) based regimen. The comorbidities assessed included hypertension, anaemia, impaired blood glucose, bone mineral disease, electrolyte imbalance, stunting and cognitive impairment. Blood pressure (BP) was measured digitally, using a paediatric cuff for the younger children. Participants were asked to sit down and relax, and their BP was taken on the left arm with an OMRON Upper ARM Blood Pressure Monitor HEM 7121J, (OMRON Healthcare Company Limited, Kyoto, Japan). The BP was taken twice, five minutes apart and the mean of the two readings taken as the final BP. They then underwent a cognitive function assessment using the Youth International HIV Dementia Scale (y-IHDS) [24]. Fasting blood glucose was measured using On Call Plus Blood Glucose Monitoring System (ACON Laboratories, Inc, San Diego, United States of America) and a venous blood sample was taken. The blood sample was analysed to determine values of serum electrolytes (potassium, chloride, bicarbonate, phosphate, calcium), kidney function (creatinine, blood urea nitrogen) measured on the Cobas 501/502 (Hitachi High technologies Corporation Tokyo, Japan). Haematological tests (complete blood count and serum ferritin) and parathyroid hormone were measured on the Cobas

- e601 (Hitachi High technologies Corporation Tokyo, Japan). All the samples were analysed in the
- 136 College of American Pathologists (CAP) accredited MRC/UVRI laboratory in Uganda.

Data analysis

135

137

- Data were collected in REDCap (2019, Vanderbilt University, USA) and exported to STATA
- statistical software version 18 (STATA Corp USA) for analysis. To take account of the changing
- reference values across the age group of this study, comorbidities were defined as in Table 1.

141 Table 1 Reference Ranges for the assessed comorbidities among the participants

Variable	Reference range
Blood pressure	Elevated blood pressure was between 90 th and 95 th percentile for
(mmHg)	age, sex, and height.
-	Hypertension was above 95 th percentile for children aged less
	than 13 years. Those above 13 years of age were considered
	hypertensive if the blood pressure was above 130/80 [8]
Fasting blood glucose	Normal 70-100,
(mg/dl)	Prediabetes100-125
	Diabetic >126 [25].
Haemoglobin	11.5 < 11 years,
(g/dl)	11.9 11 and 15 years, females >15 years
	12.9 for males >15 years [26].
Ferritin (ng/mL)	12-300 for males >15 years
	10-150 for females > 15 years
	7-142 males and females 10-14 years (20).
Red blood cells	4.7-6.1 for males
	4.2-5.4 for females
Haematocrit	0.35-0.48 for all ages [27]
Mean Corpuscular Volume	77.8-91.1 males 6-11 years
(MCV) (fL)	79.9-93.0 males 12-14 years
	82.5-98.0 males 15-17 years
	78.2-97.9 males >18 years
	77.8-91.1 females: 6-11 years
	79.9-93.0 females 12-14 years
	82.5-98.0 females 15-17 years
	78.2-97.9 females >18 years [28].
Mean Corpuscular	25-33 pg/cell for all ages and sexes [29].
Haemoglobin (MCH)	
White blood cells (µL)	4-10.5 X 10 ³ / for all ages and sexes
Platelets	150-400 for all ages [27]
Parathyroid hormone	15-59 for 10 years,
(pg/ml)	15-68 for 11 to 17 years
	15-65 for 8 to 24 years [30].
Serum calcium (mg/dl)	9.4-10.3 for 10 to 12 years
	9.1-10.2 for males aged 12 to 24 years.
	8.8-10 for females aged 12 and above [31].
	o.o-10 for females aged 12 and above [51].

Serum Phosphate (mg/dl)	3.6-5.8 for 10 -12 years,
	2.3-4.5 for 12 -20 years [32].
	2.5 to 4.5 for 21 to 24 years [33].
Blood urea nitrogen	6-20 for 10-to-17-years
(mg/dl)	8-24 for males 18 to 24 years,
	7-2 for females 18-24 years [34].
Serum Potassium (mmol/l)	3.6-5.2 for all ages [34].
Serum chloride (mmol/l)	102-112 for 10 to 17 years
	98 to 107 for 18 to 24 years [34].
Serum bicarbonate	21-29 in males
(mmol/l)	22-29 in females [34].
Cognitive impairment	<10 on the (y-IHDS) [24].

Statistical methods

Demographic and clinical characteristics were summarised by case/control status as number and percentage (categorical variables), and means and standard deviations, or medians and interquartile ranges (continuous variables) for the parametric data. A subgroup analysis of the cases that had eGFR <60ml/min/1.73m2 was also conducted. Associations of case/control status with comorbidities were assessed using logistic regression to estimate odds ratios and 95% CI. In modelling adjusted odds ratios for the association between case/control status and haematological or biochemical covariates we adjusted for age as a continuous variable, sex and viral suppression. P-values were estimated using likelihood-ratio tests. Post-hoc, to explore the extent to which differences in biochemical and haematological parameters were affected by adherence to anti-retroviral medication, we also conducted an analysis restricting to cases and controls who were virally suppressed. We also assessed the relationship between eGFR and selected haematological and biochemical factors using scatter plots and correlation coefficients to determine how they changed with changes in eGFR.

Results

We recruited 96 cases and 196 controls. Cases were more likely to be male (59.4% vs 36.2%) and to be younger (88.5% vs 46.4%) with a lower mean age compared to controls (15.3 years vs 17.8 years). After adjusting for age and sex, cases were more likely to be virally non suppressed, have proteinuria, and to have ACR above 30mg/g (Table 2).

Table 2: Distribution and associations of CKD with demographic and clinical characteristics among YPLHIV

Variable	Total N=292	Case N=96	Control N=196	OR (95% CI)*	P value
Sex					
Male	128 (43.8%)	57 (59.4%)	71 (36.2%)	1	
Female	164 (56.2%)	39 (40.6%)	125 (63.8%)	0.39 (0.23-0.64)	<0.001
Age (years)#	16.9 (3.6)	15.3 (2.8)	17.8 (3.6)	0.80 (0.74-0.87)	<0.001
10-17	176 (60.3%)	85 (88.5%)	91 (46.4%)	1	
18-24	116 (39.7%)	11 (11.5%)	105 (53.6%)	0.11 (0.06-0.22)	<0.001
Address					
Kam pala	175 (59.9%)	57 (59.4%)	118 (60.2%)	1	
Wakiso	101 (34.6%)	34 (35.4%)	67 (34.2%)	1.05 (0.62-1.77)	0.97
Other	16 (5.5%)	5 (5.2%)	11 (5.6%)	0.94 (0.31-2.83)	
Religion					
Christian	207 (70.9%)	65 (67.7%)	142 (72.4%)	1	
Moslem	83 (28.4%)	31 (32.3%)	52 (26.5%)	1.30 (0.76-2.22)	0.33
Other	2 (0.7%)	0 (0.0%)	2 (1.0%)	-	
Social Economic Status					
Lowest	100 (34.3%)	35 (36.5%)	65 (33.2%)	1	
Middle	97 (33.2%)	34 (35.4%)	63 (32.1%)	1.00 (0.55-1.79)	0.53
Highest	95 (32.5%)	27 (28.1%)	68 (34.7%)	0.73 (0.40-1.35)	_
Is child in school					
No	85 (29.1%)	20 (20.8%)	65 (33.2%)	1	
Yes	207 (70.9%)	76 (79.2%)	131 (66.8%)	1.89 (1.06-3.35)	0.03
Marital Status					
Married	14 (4.8%)	2 (2.1%)	12 (6.1%)	1	
Never married	278 (95.2%)	94 (97.9%)	184 (93.9%)	3.07 (0.67-13.97)	0.10
Tribe					
Ganda	188 (64.4%)	67 (69.8%)	121 (61.7%)	1	0.13
Other tribes	88 (30.1%)	22 (22.9%)	66 (33.7%)	0.60 (0.34-1.06)	_
Non-Ugandan	16 (5.5%)	7 (7.3%)	9 (4.65)	1.40 (0.50-3.94)	_
Body mass Index					
Normal	166 (60.6%)	41 (43.2%)	136 (69.4%)	1	<0.39
Underweight (BMI<19)	86 (31.4%)	49 (51.6%)	43 (21.9%)	1.44 (0.71-2.92)	-
Overweight (BMI>25)	22 (8.0%)	5 (5.3%)	17 (8.7%)	1.77 (0.57-5.50)	_
Mid upper arm					
circumference					
Normal	264 (90.7%)	84 (88.4%)	180 (91.8%)	1	
Malnourished	27 (9.3%)	11 (11.6%)	16 (8.2%)	1.47 (0.65-3.31)	0.35
Weight (Kg)#	49.9 (12.1%)	45.35 (11.1%)	52.18 (11.9%)	0.95 (0.93-0.97)	<0.001
Muscle mass					
Normal muscle mass	235 (84.5%)	74 (84.1%)	161 (84.7%)	1	
Abnormal muscle mass	43 (15.5%)	14 (15.9%)	29 (15.3%)	1.05 (0.52-2.10)	0.89
TDF based regimen					
No TDF or ATV	69 (23.6%)	28 (29.2%)	41 (20.9%)	1	
On TDF or ATV	223 (76.4%)	68 (70.8%)	155 (79.1%)	0.64 (0.36-1.12)	0.12
Virally suppressed (VL <1,000 copies per ml)					


Yes	263 (90.4%)	80 (83.3%)	183 (93.8%)	1	
No	28 (9.6%)	16 (16.7%)	12 (6.2%)	3.73 (1.53-9.12)	0.006
Proteinuria					
Negative	203 (69.5%)	52 (54.2%)	151 (77.0%)	1	
Positive	89 (30.5%)	44 (45.8%)	45 (23.0%)	4.19 (2.28-7.72)	<0.001
Albumin creatinine					
ratio					
Below 30mg/g	261 (89.4%)	75 (78.1%)	186 (94.9%)	1	
Above 30mg/g	31 (10.6%)	21 (21.9%)	10 (5.1%)	6.43 (2.67-15.48)	<0.001

^{*}adjusted for age and sex # mean and standard deviation. Proteinuria was measured on dipstick

Associations between CKD and comorbidities among YPLHIV

Cases had lower odds of having a high MCV (aOR=0.24, 95% CI 0.09-0.64), and higher odds of hyperphosphatemia (aOR=3.66, 95% CI 1.21 -5.84), and higher odds of hyperchloremia (aOR=2.55, 95% CI 1.36 -4.77), after adjustment for age, sex, and viral suppression. There was no evidence of an association between CKD and blood pressure, impaired blood glucose, other biochemical and haematological parameters and cognitive function. These results did not change when analysis was restricted to those who were virally suppressed (Table 3). Analysis of eGFR and selected variables showed no correlation between eGFR and those variables. (Figure 1). Of note, two participants had potassium levels below 3.5mmol/l and six had elevated levels above 6 mmol/l and 125 (42.8%) were acidotic. Results for the cases that had eGFR <60ml/min/1.73m2 are reported in supplementary tables 1 and 2.

Figure 1 Relationship between eGFR and selected biochemical markers



Cases with eGFR<60mls/min/1.73m²

Of the seven participants with eGFR <60ml/min/1.73m², five were male, below 18 years of age and on a TDF based regimen, three had proteinuria and five had an ACR above 30mg/g. The mean systolic blood pressure was lower than that of the participants with eGFR below 90ml/min/1.73m² and only one was hypertensive, two had prediabetic range blood glucose levels, one had anaemia, two had leukopenia, one had thrombocytosis and four had increased levels of parathyroid hormone and 5 had impaired cognition (Table 3).

Table 3: Distribution and associations of CKD with comorbidities among PLWH

Variable	Total n=292	Case (n=96)	Control (n=196)	Adjusted OR for age, sex and viral suppression	P value	Restricted to virally suppressed N=263
Blood pressure (mmhg)						
Systolic blood pressure ^a	111.7 (12.1)	110.9 (12.0)	112.1 (12.1)			
Diastolic blood pressure ^a	71.4 (8.8)	69.8 (8.9)	72.1 (8.7)			
Normal	204 (69.9%)	67 (69.8%)	137 (69.9%)	1		1
Elevated	38 (13.0%)	14 (14.6%)	24 (12.2%)	1.05 (0.48- 2.35)	0.93	0.99 (0.43-2.24)
Hypertensive	50 (17.1%)	15 (15.6%)	35 (17.9%)	1.15 (0.54- 2.47)	-	1.14 (0.49-2.64)
Blood Sugar (mg/dl)						
Blood glucose a	94.1 (15.2)	93.7 (16.2)	94.2 (14.6)			
Normal	205 (70.2)	65 (67.7%)	140 (71.4%)	1		1

Prediabetic	78 (26.7)	28 (29.2%)	50 (25.5%)	1.03 (0.56-1.92)	0.99	0.83 (0.42-1.64)
Diabetic	9 (3.1)	3 (3.1%)	6 (3.1%)	1.08 (0.24-4.96)	=	1.47 (0.30-7.19)
Anaemia status (g/dl)						
Haemoglobin ^a	13.3 (1.7)	13.4 (1.3)	13.3 (1.9)			
No anaemia	229 (78.4%)	76 (79.2%)	153 (78.1%)	1		1
Anaemic	63 (21.6%)	20 (20.8%)	43 (21.9%)	1.12 (0.58-2.19)	0.73	1.09 (0.54-2.19)
Serum Ferritin (ng/ml)						
Ferritin ^b	36.4 (18.8-69.3)	45.1 (22.5- 72.4)	34.0 (15.6- 64.1)			
Normal	254 (86.9)	86 (86.9%)	168 (85.7%)	1		1
Low ferritin	23 (7.9)	4 (4.2%)	19 (9.7%)	0.67 (0.21-2.18)	0.88	0.81 (0.24-2.69)
High ferritin	15 (5.2)	6 (6.2%)	9 (4.6%)	1.42 (0.41-4.94)		1.70 (0.44-6.48)
Red blood cells (10^6/µ						
Absolute count ^a	4.8 (0.6)	4.9 (0.6)	4.7 (0.6)			
Normal count	209 (71.6)	67 (69.8)	142 (72.5)	1		1
Low count	68 (23.3)	24 (25.0)	44 (22.5)	0.62 (0.30-1.25)	0.39	0.56 (0.26-1.21)
High count	15 (5.1)	5 (5.2)	10 (5.0)	0.86 (0.26-2.89)		0.93 (0.25-3.49)
Haematocrit (%)						
Haematocrit ^a	41.6 (4.92)	41.9 (3.9)	41.4 (5.4)			
Normal	242 (82.9)	89 (92.7)	153 (78.1)	1		1
Low haematocrit	19 (6.5)	1 (1.0)	18 (9.2)	0.12 (0.02-1.17)	0.01	-
High haematocrit	131 (10.6)	6 (6.3)	25 (12.8)	0.38 (0.13-1.06)		0.35 (0.11-1.03)
Mean Corpuscular volu	me (MCV) (pg)					
MCV a	87.3 (8.4)	86.5 (7.4)	87.7 (8.8)			
Normal	200 (68.5)	68 (70.8%)	132 (67.3%)	1		1
Low MCV	53 (18.2)	20 (20.8%)	33 (16.8%)	1.17 (0.58-2.38)	0.02	1.19 (0.57-2.48)
High MCV	39 (13.6)	8 (8.3%)	31 (15.8%)	0.24 (0.09-0.64)		0.19 (0.07-0.58)
White blood cell count ((μL)					
Absolute b	4.9 (4.0-5.9)	5.0 (4.1-6.0)	4.9 (4.0-5.9)			
Normal	223 (76.4)	75 (78.1)	148 (75.5)	1		1
Leukopenia	68 (23.3)	21 (21.9)	47 (24.0)	0.87 (0.45-1.68)	0.67	1.08 (0.53-2.18)
Leucocytosis	1 (0.3)	0 (0.0)	1 (0.5)	-		-
Platelets (10^3/µL)						
Count a	342.5 (90.9)	332.6 (75.2)	347.3 (97.5)			
Normal	258 (88.4)	88 (91.7)	170 (86.7)	1		1
Thrombocytopenia	2 (0.7)	0 (0.0)	2 (1.0)	-		-
Thrombocytosis	32 (10.9)	8 (8.3)	24 (12.2)	0.58 (0.23-1.47)	0.25	0.46 (0.17-1.23)
Parathyroid hormone ()	pg/ml)					
PTH ^b	57.7 (42.6-79.3)	62.7 (44.9- 80.3)	55.6 (42-79.1)			
Normal parathyroid	183 (62.7)	57 (59.4%)	126 (64.3%)	1		1
Hyperparathyroidism	109 (37.3)	39 (40.6%)	70 (35.7%)	0.87 (0.50-1.57)	0.68	0.74 (0.40-1.36)
Serum Calcium (mg/dl)						
Calcium ^a	2.30 (0.1)	2.29 (0.17)	2.28 (0.11)			
Normal	194 (66.4)	61 (63.5%)	133 (67.9%)	1		1
Hypocalcaemia	94 (32.2)	34 (35.4%)	60 (30.6%)	0.55 (0.29-1.04)	0.11	0.42 (0.21-0.86)
Hypercalcemia	4 (1.4)	1 (1.0%)	3 (1.5%)	1.37 (0.12-15.17)		2.68 (0.19-37.3)
Serum Phosphate (mg/d	11)					
Phosphate b	1.2 (1.0-1.4)	1.4 (1.1-1.5)	1.1 (0.95-1.3)			
	<u> </u>		<u> </u>			

242 (82.9)	70 (72.9%)	172 (87.7%)	1		1
11 (3.8)	2 (2.1%)	9 (4.6%)	0.89 (0.17-4.58)	0.02	0.92 (0.17-4.75)
39 (13.4)	24 (22.0%)	15 (7.7%)	2.56 (1.21-5.42)		2.59 (1.18-5.67)
g/dl)					
2.7 (0.9)	2.8 (0.93)	2.7 (0.83)			
167 (57.2%)	58 (72.2%)	109 (55.6%)	1		1
125 (42.8%)	22 (27.8%)	87 (44.4%)	0.79 (0.45-1.39)	0.43	0.80 (0.44-1.44)
/1)					
4.7 (0.5)	4.8 (0.53)	4.6 (0.52)			
257 (88.0%)	82 (85.4%)	175 (89.3%)	1		1
2 (0.7%)	0 (0.0%)	2 (1.0%)	-		-
33 (11.3%)	14 (14.6%)	19 (9.7%)	1.52 (0.67-3.44)	0.37	1.61 (0.69-3.71)
)					
103.2 (8.6)	103.1 (9.19)	103.3 (8.36)			
197 (67.5%)	58 (60.4%)	139 (70.9%)	1		1
19 (6.5%)	6 (6.3%)	13 (6.6%)	1.26 (0.40-3.97)		0.99 (0.29-3.40)
76 (26.0%)	32 (33.3%)	44 (22.5%)	2.43 (1.28-4.59)	0.02	2.37 (1.2-4.68)
ol/l)					
20.6 (2.6)	20.2 (2.4)	20.7 (2.6)			
103 (35.3%)	32 (33.3%)	71 (36.2%)	1		1
188 (64.4%)	64 (66.7%)	124 (63.3%)	1.24 (0.67-2.26)	0.49	1.19 (0.63-2.24)
1 (0.3%)	0 (0.0%)	1 (0.5%)	-		-
171 (82.2%)	66 (75.9%)	105 (86.8%)	1		1
37 (17.8%)	21 (24.1%)	16 (13.2%)	1.57 (0.71-3.47)	0.26	1.28 (0.55-2.99)
169 (57.9%)	48 (50.0%)	121 (61.7%)	1		1
123 (42.1%)	48 (50.0%)	75 (38.3%)	1.42 (0.81-2.52)	0.22	1.40 (0.77-2.55)
	11 (3.8) 39 (13.4) g/dl) 2.7 (0.9) 167 (57.2%) 125 (42.8%) /I) 4.7 (0.5) 257 (88.0%) 2 (0.7%) 33 (11.3%)) 103.2 (8.6) 197 (67.5%) 19 (6.5%) 76 (26.0%) iol/l) 20.6 (2.6) 103 (35.3%) 188 (64.4%) 1 (0.3%) 171 (82.2%) 37 (17.8%)	11 (3.8) 2 (2.1%) 39 (13.4) 24 (22.0%) g/dl) 2.7 (0.9) 2.8 (0.93) 167 (57.2%) 58 (72.2%) 125 (42.8%) 22 (27.8%) /I) 4.7 (0.5) 4.8 (0.53) 257 (88.0%) 82 (85.4%) 2 (0.7%) 0 (0.0%) 33 (11.3%) 14 (14.6%)) 103.2 (8.6) 103.1 (9.19) 197 (67.5%) 58 (60.4%) 19 (6.5%) 6 (6.3%) 76 (26.0%) 32 (33.3%) iol/I) 20.6 (2.6) 20.2 (2.4) 103 (35.3%) 32 (33.3%) 188 (64.4%) 64 (66.7%) 1 (0.3%) 0 (0.0%)	11 (3.8) 2 (2.1%) 9 (4.6%) 39 (13.4) 24 (22.0%) 15 (7.7%) g/dl) 2.7 (0.9) 2.8 (0.93) 2.7 (0.83) 167 (57.2%) 58 (72.2%) 109 (55.6%) 125 (42.8%) 22 (27.8%) 87 (44.4%) /I) 4.7 (0.5) 4.8 (0.53) 4.6 (0.52) 257 (88.0%) 82 (85.4%) 175 (89.3%) 2 (0.7%) 0 (0.0%) 2 (1.0%) 33 (11.3%) 14 (14.6%) 19 (9.7%)) 103.2 (8.6) 103.1 (9.19) 103.3 (8.36) 197 (67.5%) 58 (60.4%) 139 (70.9%) 19 (6.5%) 6 (6.3%) 13 (6.6%) 76 (26.0%) 32 (33.3%) 44 (22.5%) tol/I) 20.6 (2.6) 20.2 (2.4) 20.7 (2.6) 103 (35.3%) 32 (33.3%) 71 (36.2%) 188 (64.4%) 64 (66.7%) 124 (63.3%) 1 (0.3%) 0 (0.0%) 1 (0.5%) 171 (82.2%) 66 (75.9%) 105 (86.8%) 37 (17.8%) 21 (24.1%) 16 (13.2%)	11 (3.8) 2 (2.1%) 9 (4.6%) 0.89 (0.17-4.58) 39 (13.4) 24 (22.0%) 15 (7.7%) 2.56 (1.21-5.42) g/dl) 2.7 (0.9) 2.8 (0.93) 2.7 (0.83) 167 (57.2%) 58 (72.2%) 109 (55.6%) 1 125 (42.8%) 22 (27.8%) 87 (44.4%) 0.79 (0.45-1.39) //) 4.7 (0.5) 4.8 (0.53) 4.6 (0.52) 257 (88.0%) 82 (85.4%) 175 (89.3%) 1 2 (0.7%) 0 (0.0%) 2 (1.0%) - 33 (11.3%) 14 (14.6%) 19 (9.7%) 1.52 (0.67-3.44)) 103.2 (8.6) 103.1 (9.19) 103.3 (8.36) 197 (67.5%) 58 (60.4%) 139 (70.9%) 1 19 (6.5%) 6 (6.3%) 13 (6.6%) 1.26 (0.40-3.97) 76 (26.0%) 32 (33.3%) 44 (22.5%) 2.43 (1.28-4.59) sol/I) 20.6 (2.6) 20.2 (2.4) 20.7 (2.6) 103 (35.3%) 32 (33.3%) 71 (36.2%) 1 188 (64.4%) 64 (66.7%) 124 (63.3%) 1.24 (0.67-2.26) 1 (0.3%) 0 (0.0%) 1 (0.5%) -	11 (3.8) 2 (2.1%) 9 (4.6%) 0.89 (0.17-4.58) 0.02 39 (13.4) 24 (22.0%) 15 (7.7%) 2.56 (1.21-5.42) g/dI) 2.7 (0.9) 2.8 (0.93) 2.7 (0.83) 167 (57.2%) 58 (72.2%) 109 (55.6%) 1 125 (42.8%) 22 (27.8%) 87 (44.4%) 0.79 (0.45-1.39) 0.43 //I) 4.7 (0.5) 4.8 (0.53) 4.6 (0.52) 257 (88.0%) 82 (85.4%) 175 (89.3%) 1 2 (0.7%) 0 (0.0%) 2 (1.0%) - 33 (11.3%) 14 (14.6%) 19 (9.7%) 1.52 (0.67-3.44) 0.37) 103.2 (8.6) 103.1 (9.19) 103.3 (8.36) 197 (67.5%) 58 (60.4%) 139 (70.9%) 1 19 (6.5%) 6 (6.3%) 13 (6.6%) 1.26 (0.40-3.97) 76 (26.0%) 32 (33.3%) 44 (22.5%) 2.43 (1.28-4.59) 0.02 ol/I) 20.6 (2.6) 20.2 (2.4) 20.7 (2.6) 103 (35.3%) 32 (33.3%) 71 (36.2%) 1 188 (64.4%) 64 (66.7%) 124 (63.3%) 1.24 (0.67-2.26) 0.49 1 (0.3%) 0 (0.0%) 1 (0.5%) -

187 Discussion

We set out to assess comorbidities associated with CKD among YPLHIV in Uganda. YPLHIV with CKD were more likely than controls to have hyperphosphatemia and hyperchloremia and were less likely to have high MCV and high haematocrit. Although the prevalence of common comorbidities such as hypertension, anaemia, impaired glucose metabolism, cognitive impairment and stunting was high, they were not associated with having CKD among the YPLHIV in this study.

We included a sufficiently large number of cases and controls and assessed multi body systems for comorbidities. There is little literature on the comorbidities faced by young people with the double burden of CKD and HIV in SSA. This is surprising given that 90% of young people living with HIV reside in SSA and they are at high risk of developing complications of HIV such as CKD [35, 36].

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Findings from the current study are thus discussed here in comparison with those in either young people living with CKD and not HIV, or with YPLHIV or adults with CKD in the general population. We might not have observed substantial differences between YPLHIV with CKD and those without for a variety of reasons. 1) HIV itself causes similar complications to CKD in the cardiovascular, musculoskeletal, and haematological systems, including stunting [13]. The cases were more likely to have HIV viral non-suppression, an important difference since uncontrolled HIV can lead to more complications. 2) The cases (except for the seven with eGFR<60ml/ml/1.73m²) were still in the early stages of CKD with an eGFR between 60 and 90 ml/min/1.73m², most complications develop with later stages of CKD [37]. 3) CKD status of the controls was determined only at baseline, any of them could have developed an eGFR less than 90ml/min/1.73m² during the follow up time, making them a case and obscuring the differences. 4) Discerning participants with derangements in the biochemical and haematological markers was also challenging. Reference values for most of these markers were derived from American populations and those of African populations are mostly unknown [38]. Using these values could have led to misclassification of the YPLHIV and obscured associations [39]. This study shows that the cases have started developing complications and could get worsening kidney function and eventual kidney failure. The cases had hyperphosphatemia, but not low calcium. This was also true for the CKiD study in the United States of America that enrolled children with CKD, mostly of congenital origin. As GFR decreased, hyperphosphatemia and increased levels of PTH and eventually low levels of calcium emerged [40]. The cases in this study may be on their way to developing bone mineral disease which is associated with cardiovascular events, cognitive impairment and stunting [41]. The cases in our study had higher levels of serum chloride than controls. Serum chloride has been suggested as predictor of CKD progression and could show that the YPLHIV are in danger of CKD progression [42]. Of concern, we have identified people with both dangerously high and low potassium levels. We cannot exclude that these are due to haemolysis or analytical errors,) but this highlights the importance of better monitoring and clinical management of biochemical abnormalities in this vulnerable patient group.

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

YPLHIV with CKD have been shown to have atypical presentation patterns which are different from adults living with HIV where we draw most of the comparisons [13]. For example, common complications such as hypertension and anaemia were not associated with CKD in this study. A study in Nigeria on 24 children 6 to 17 years of age with CKD and age and sex matched controls found that prevalence of hypertension increased as the CKD stage increased [43]. The participants in this study were not living with HIV and had more advanced stages of CKD compared to our participants. Haemoglobin was not associated with eGFR in this study. Anaemia is more prevalent in advanced stages of CKD with GFR less than 60 ml/min and since the YPLHIV were still in lower stages, this could explain the lack of association [44, 45]. There is still a lot that is unknown about the comorbidities associated with CKD among YPLHIV. Our results call for more studies that characterise the spectrum and presentation of chronic comorbidities among YPLHIV with CKD for a more comprehensive understanding [5]. Comparison of YPLHIV with CKD with HIV negative controls might explain the contribution of HIV. Conclusion The pattern of comorbidities among YPLHIV with CKD is uncertain and difficulties may relate to difficulty determining true kidney function and normal ranges in this population. Further studies are needed to discern the pattern of CKD complications to improve management efforts and clinical outcomes. **Ethical considerations** This study was approved by the Uganda Virus Research Institute (UVRI) Research Ethics Committee with reference number GC/127/946, the Uganda National Council of Science and Technology (reference number HS2578ES) and the London School of Hygiene and Tropical Medicine (reference 28797). Informed consent/assent was provided by all participants. Age-appropriate information about the study was provided prior to consent by the study nurses. All the participants aged more than 18 years provided a written informed consent. Those aged below 18 years (child) provided written assent

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

and their caregivers provided a written informed consent. The studies were conducted in accordance with the declaration of Helsinki. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. **Conflicts of interest** The authors declare no conflict of interest. **Funding statement** Support for the PhD studies was provided by Fogarty International Centre, National Institutes of Health (grant #2D43TW009771-06) HIV and co-infections in Uganda. Esther Nasuuna, Doctoral Research Fellow, NIHR131273 is funded by the NIHR for this research project. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care. Acknowledgments We wish to acknowledge the participants, their caregivers and the facility staff where this study took place. We also acknowledge the study team, Miss Evelyn Natuha, Miss Stella Mirembe and Mr. Malcolm Lwanga. We acknowledge the KCCA leadership and the PEPFAR program that supports HIV care for the YPLHIV. Supplementary material There are two tables in the supplementary material section that show the sub analysis of cases that had an eGFR <60ml/min/1.73m2. Supplementary table 1: Demographic and clinical characteristics of the cases with eGFR less than 60ml/min/1.73m² Supplementary table 2: Distribution of comorbidities in the cases with eGFR less than 60ml/min/1.73m2

References

274

275

- 276 1. Snively CS, Gutierrez C. Chronic kidney disease: prevention and treatment of common
- complications. American family physician. 2004;70(10):1921-8.
- 278 2. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. The
- 279 lancet. 2021;398(10302):786-802.
- 280 3. Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. Nature
- 281 Reviews Neurology. 2009;5(10):542-51.
- 282 4. Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care.
- 283 2008;35(2):329-vii.
- 5. Bello AK, Alrukhaimi M, Ashuntantang GE, Basnet S, Rotter RC, Douthat WG, et al.
- 285 Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.
- Kidney international supplements. 2017;7(2):122-9.
- 287 6. Di Lullo L, House A, Gorini A, Santoboni A, Russo D, Ronco C. Chronic kidney disease and
- cardiovascular complications. Heart Failure Reviews. 2015;20(3):259-72.
- 289 7. Sarnak MJ. Cardiovascular complications in chronic kidney disease. American Journal of
- 290 Kidney Diseases. 2003;41:11-7.
- 291 8. Flynn JT, Falkner BE. New Clinical Practice Guideline for the Management of High Blood
- Pressure in Children and Adolescents. Hypertension (Dallas, Tex: 1979). 2017;70(4):683-6.
- 9. Hou YC, Lu CL, Lu KC. Mineral bone disorders in chronic kidney disease. Nephrology.
- 294 2018;23:88-94.
- 295 10. Kaspar C, Bholah R, Bunchman T. A review of pediatric chronic kidney disease. Blood
- 296 purification. 2016;41(1-3):211-7.
- 297 11. Silverstein DM. Growth and nutrition in pediatric chronic kidney disease. Frontiers in
- 298 pediatrics. 2018;6:205.
- 299 12. Arnold R, Issar T, Krishnan AV, Pussell BA. Neurological complications in chronic kidney
- 300 disease. JRSM Cardiovascular Disease. 2016;5:2048004016677687.
- 301 13. Frigati LJ, Ameyan W, Cotton MF, Gregson CL, Hoare J, Jao J, et al. Chronic comorbidities
- 302 in children and adolescents with perinatally acquired HIV infection in sub-Saharan Africa in the era of
- antiretroviral therapy. The Lancet Child & Adolescent Health. 2020;4(9):688-98.
- 304 14. Gulati S, Langman C. Chronic kidney disease in children. 2020.
- 305 15. Swanepoel CR, Atta MG, D'Agati VD, Estrella MM, Fogo AB, Naicker S, et al. Kidney
- 306 disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global
- 307 Outcomes (KDIGO) Controversies Conference. Kidney international. 2018;93(3):545-59.
- 308 16. Becherucci F, Roperto RM, Materassi M, Romagnani P. Chronic kidney disease in children.
- 309 Clinical kidney journal. 2016;9(4):583-91.

- 310 17. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka VR, Warady BA, et
- al. Improved equations estimating GFR in children with chronic kidney disease using an
- immunonephelometric determination of cystatin C. Kidney International. 2012;82(4):445-53.
- 313 18. Selistre L, Rabilloud M, Cochat P, de Souza V, Iwaz J, Lemoine S, et al. Comparison of the
- 314 Schwartz and CKD-EPI equations for estimating glomerular filtration rate in children, adolescents,
- and adults: a retrospective cross-sectional study. PLoS medicine. 2016;13(3):e1001979.
- 316 19. Filler G, Ferris M, Gattineni J. Assessment of kidney function in children, adolescents, and
- young adults. Pediatric Nephrology: Springer; 2022. p. 145-71.
- 318 20. Delanaye P, Glassock RJ, Pottel H, Rule AD. An age-calibrated definition of chronic kidney
- disease: rationale and benefits. The Clinical Biochemist Reviews. 2016;37(1):17.
- 320 21. Lameire NH, Levin A, Kellum JA, Cheung M, Jadoul M, Winkelmayer WC, et al.
- 321 Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney
- Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney international.
- 323 2021;100(3):516-26.
- 324 22. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, et al. Kidney
- 325 Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice
- 326 guideline for the evaluation and management of chronic kidney disease. Kidney international
- 327 supplements. 2013;3(1):1-150.
- 328 23. Inc. RD. CYSC2: Tina-quant Cystatin C Gen.2. 2023.
- 329 24. Phillips NJ, Thomas KGF, Myer L, Sacktor N, Zar HJ, Stein DJ, et al. Screening for HIV-
- associated neurocognitive disorders in perinatally infected adolescents: youth-International HIV
- 331 Dementia Scale validation. AIDS. 2019;33(5).
- 332 25. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and
- 333 Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes
- 334 Association. Diabetes Care. 2018;41(12):2648-68.
- 335 26. Organization WH. Haemoglobin concentrations for the diagnosis of anaemia and assessment
- of severity. World Health Organization; 2011.
- 337 27. NHS North Bristol. Children's Reference Ranges for FBC Bristol [Available from:
- 338 https://www.nbt.nhs.uk/sites/default/files/Childrens%20FBC%20Reference%20Ranges.pdf.
- 339 28. Mayo Clinic Laboratories. Complete Blood Cell Count (CBC) with Differential, Blood: Mayo
- Foundation for Medical Education and Research.; 2024 [cited 2024 30th January]. Available from:
- 341 https://pediatric.testcatalog.org/show/KS.
- 342 29. Gligoroska JP, Gontarev S, Dejanova B, Todorovska L, Stojmanova DS, Manchevska S. Red
- 343 blood cell variables in children and adolescents regarding the age and sex. Iranian journal of public
- 344 health. 2019;48(4):704.
- 345 30. Mayo Clinic Laboratories. Parathyroid Hormone, Serum: Mayo Foundation for Medical
- Education and Research.; 2024 [cited 2024 30th January]. Available from:
- 347 https://pediatric.testcatalog.org/show/BUN.
- 34. Lietman SA, Germain-Lee EL, Levine MA. Hypercalcemia in children and adolescents. Curr
- 349 Opin Pediatr. 2010;22(4):508-15.

- 350 32. KDOQI N. Clinical practice guidelines for bone metabolism and disease in children with
- 351 chronic kidney disease. Am J Kidney Dis. 2005;46:S1-S100.
- 352 33. Bazydlo LAL, Needham M, Harris NS. Calcium, Magnesium, and Phosphate. Laboratory
- 353 Medicine. 2014;45(1):e44-e50.
- 34. Mayo Clinic Laboratories. Basic Metabolic Panel, Serum: Mayo Foundation for Medical
- Education and Research.; 2024 [Available from: https://pediatric.testcatalog.org/show/BMAMA.
- 35. UNFPA. UNFPA SUPPORT TO THE HIV RESPONSE AN OVERVIEW (2016 to 2019).
- 357 Geneva: United Nations 2020.
- 358 36. Bhimma R. HIV-Related Kidney Diseases. In: Bobat R, editor. HIV Infection in Children and
- 359 Adolescents. Cham: Springer International Publishing; 2020. p. 143-52.
- 360 37. George C, Mogueo A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease
- in low-income to middle-income countries: the case for increased screening. BMJ Glob Health.
- 362 2017;2(2):e000256.
- 363 38. Clement EZ, Collins OO, Lisa AM. Laboratory Reference Intervals in Africa. In: Terry EM,
- editor. Blood Cell. Rijeka: IntechOpen; 2012. p. Ch. 15.
- 365 39. Buchanan AM, Fiorillo SP, Omondi MW, Cunningham CK, Crump JA. Establishment of
- 366 biochemistry reference values for healthy Tanzanian infants, children and adolescents in Kilimanjaro
- 367 Region. Tropical medicine & international health: TM & IH. 2015;20(11):1569-77.
- 368 40. Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, et al. Disordered
- 369 FGF23 and mineral metabolism in children with CKD. Clinical Journal of the American Society of
- 370 Nephrology. 2014;9(2):344-53.
- Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in
- 372 children. Pediatric Nephrology. 2008;23(2):195-207.
- 373 42. Khatri M, Zitovsky J, Lee D, Nayyar K, Fazzari M, Grant C. The association between serum
- 374 chloride levels and chronic kidney disease progression: a cohort study. BMC nephrology.
- 375 2020;21(1):1-10.
- 376 43. Adiele DK, Ojinnaka NC, Okafor HU, Chinawa JM. Blood pressure trend in children with
- 377 chronic kidney disease in Nigeria, Sub Saharan African region. Nigerian Journal of Medicine.
- 378 2023;32(4):407-11.

- 379 44. Schrauben SJ, Berns JS. Chapter 30 Hematologic Complications of Chronic Kidney
- 380 Disease—Anemia and Platelet Disorders. In: Kimmel PL, Rosenberg ME, editors. Chronic Renal
- 381 Disease (Second Edition): Academic Press; 2020. p. 463-75.
- 382 45. Rayner HC, Thomas ME, Milford DV. Full Blood Count: Haematological Changes in Kidney
- Diseases. Understanding Kidney Diseases. Cham: Springer International Publishing; 2020. p. 207-17.